Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct-Dec;47(4):510-516.
doi: 10.4103/ijcm.ijcm_1388_21. Epub 2022 Dec 14.

The Effectiveness of SARS-CoV-2 Vaccination in Preventing Severe Illness and Death - Real-world Data from a Cohort of Patients Hospitalized with COVID-19

Hari Krishna Raju Sagiraju  1 , Arunmozhimaran Elavarasi  2 , Nishkarsh Gupta  3 , Rohit Kumar Garg  4 , Saurav Sekhar Paul  4 , Saurabh Vig  3 , Prashant Sirohiya  3 , Brajesh Ratre  3 , Rakesh Garg  3 , Anuja Pandit  3 , Ram Singh  3 , Balbir Kumar  3 , Ved Prakash Meena  4 , Naveet Wig  4 , Saurabh Mittal  5 , Sourabh Pahuja  5 , Karan Madan  5 , Nupur Das  6 , Tanima Dwivedi  6 , Ritu Gupta  6 , LaxmiTej Wundavalli  7 , Angel Rajan Singh  7 , Sheetal Singh  7 , Abhinav Mishra  3 , Manisha Pandey  3 , Karanvir Singh Matharoo  3 , Sunil Kumar  8 , Anant Mohan  5 , Randeep Guleria  5 , Sushma Bhatnagar  4
Affiliations

The Effectiveness of SARS-CoV-2 Vaccination in Preventing Severe Illness and Death - Real-world Data from a Cohort of Patients Hospitalized with COVID-19

Hari Krishna Raju Sagiraju et al. Indian J Community Med. 2022 Oct-Dec.

Abstract

Background: While long-term studies on the correlates of protection, vaccine effectiveness, and enhanced surveillance are awaited for SARS-CoV-2 vaccine, studies on breakthrough infections help understand the nature and course of this illness among vaccinated individuals and guide in public health preparedness. This study aims to compare the differences in the hospitalization outcomes SARS-CoV-2 infection of fully vaccinated individuals with with those of unvaccinated and partially vaccinated individuals.

Materials and methods: Single institution observational cohort study. This study compared the differences in clinical, biochemical parameters and the hospitalization outcomes of 53 fully vaccinated individuals with those of unvaccinated (1464) and partially vaccinated (231) individuals, among a cohort of 2,080 individuals hospitalized with SARS-CoV-2 infection. Descriptive statistics and propensity-score weighted multivariate logistic regression analysis adjusting for clinical and laboratory parameters were used to compare the differences and to identify factors associated with outcomes.

Results: Completing the course of vaccination protected individuals from developing severe COVID-19 as evidenced by lower proportions of those with hypoxia, abnormal levels of inflammatory markers, requiring ventilatory support, and death compared to unvaccinated and partially vaccinated individuals. There were no differences in these outcomes among patients who received either vaccine type approved in India.

Conclusions: Efforts should be made to improve the vaccination rates as a timely measure to prepare for the upcoming waves of this highly transmissible pandemic. Vaccination rates of the communities may also guide in the planning of the health needs and appropriate use of medical resources.

Keywords: Breakthrough infection; SARS-CoV-2 vaccine; mortality; severe illness.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Temporal trends of symptom onset after 1st dose of the vaccine among those who received only one dose vaccine
See this image and copyright information in PMC

References

    1. Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2:An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. - PMC - PubMed
    1. Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152):Interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021;398:2173–84. - PMC - PubMed
    1. Geddes L. How Effective are COVID-19 Vaccines in the Real-World? [Last accessed on 2021Aug 24]. Available from: https://www.gavi.org/vaccineswork/how-effective-are-COVID-19-19-vaccines... .
    1. Olliaro P, Torreele E, Vaillant M. COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room. Lancet Microbe. 2021;2:e279–80. - PMC - PubMed
    1. Patel MK, Bergeri I, Bresee JS, Cowling BJ, Crowcroft NS, Fahmy K, et al. Evaluation of post-introduction COVID-19 vaccine effectiveness:Summary of interim guidance of the World Health Organization. Vaccine. 2021;39:4013–24. - PMC - PubMed